Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.65 |
| ▸ | SRC | P12931 | 10/20 | 0.61 |
| ▸ | HCK | P08631 | 9/20 | 0.61 |
| ▸ | GSK3A | P49840 | 7/20 | 0.61 |
| ▸ | SYK | P43405 | 6/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504135 | 0.92 | MAPK14 (0.77) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL20663723 | 0.88 | MAPK14 (0.60) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL2527570 | 0.88 | MAPK14 (0.81) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL12540421 | 0.87 | MAPK14 (0.77) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL20060625 | 0.87 | MAPK14 (0.62) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL16240690 | 0.87 | MAPK14 (0.79) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL1695605 | 0.85 | MAPK14 (0.72) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL1694481 | 0.85 | MAPK14 (0.76) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL20060580 | 0.85 | MAPK14 (0.62) | MAPK14MAPK12SRCHCKGSK3A | |
| SCHEMBL20060583 | 0.84 | MAPK14 (0.68) | MAPK14MAPK12SRCHCKGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582433-B1 | UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS | RESPIVERT LTD (GB) | 2018-04-18 | — | — | EP | disclosed |